Guglielmetti, 218 patient HCQ late treatment study: 35% lower mortality [p=0.22] https://c19p.org/guglielmetti
copied to clipboard
Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave
et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012
Retrospective 218 hospitalized patients in Italy showing non-statistically significant 35% lower mortality with HCQ, hazard ratio aHR 0.65 [0.33–1.30].
|
risk of death, 35.0% lower, RR 0.65, p = 0.22, treatment 181, control 37, adjusted per study, multivariable Cox.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Guglielmetti et al., 12/9/2020, retrospective, Italy, Europe, peer-reviewed, 16 authors, average treatment delay 8.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.